ProfileGDS5678 / 1434091_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 43% 40% 40% 41% 40% 43% 48% 41% 42% 46% 42% 41% 42% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0421243
GSM967853U87-EV human glioblastoma xenograft - Control 22.9043940
GSM967854U87-EV human glioblastoma xenograft - Control 32.9082140
GSM967855U87-EV human glioblastoma xenograft - Control 42.8846241
GSM967856U87-EV human glioblastoma xenograft - Control 52.879140
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0784743
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2025148
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9296341
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.947842
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.05746
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9715442
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8984441
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9733242
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9600442